Secured $900 million DOE task order for HALEU production expansion.
GAAP net income declined 63% year-over-year due to surging growth costs.
Operating income dropped 96% as technology and SG&A expenses spiked.
Maintains a strong $1.9 billion cash position to fund strategic expansions.
The Q1 2026 filing presents a company at a critical crossroads, balancing a massive capital infusion and government backing against deteriorating short-term operational margins. The $900 million DOE award and the $1.9 billion cash fortress provide a significant safety net, but the transition to a manufacturer is proving expensive, as evidenced by the spike in advanced technology costs and the swing to negative operating cash flow. Ultimately, the investment thesis hinges on the successful execution of the Piketon and Oak Ridge expansions. If Centrus can successfully replace Russian supply with domestic production and convert its $2.4 billion contingent backlog into realized revenue, the current spending will be viewed as a necessary investment in growth. However, the reliance on DOE appropriations and the fragility of the Russian supply chain introduce a level of binary risk that offsets the current liquidity strength.